The authors concluded that in clinical situations in which no tissue is available, the combination of cytological imprints and PD-L1 positive CTCs in the blood provides a predictive tool for tumoral PD-L1 status in NSCLC patients [50]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.